目的 分析新型冠状病毒(简称新冠病毒)不同变异株感染者流行病学主要指标和临床表现差异,为新冠病毒感染疫情的防控提供参考依据。方法 收集2020—2022年安徽省新冠病毒感染者的人口学、流行病学、临床表现及实验室检测等资料,使用SPSS 21.0对不同变异株感染者的流行病学和临床特征进行统计分析。结果 共纳入2 416例新冠病毒感染者,其中原始株感染990例、B.1.1.317进化分支感染22例、Delta感染12例、Omicron感染1 392例。新冠病毒不同变异株感染者病例分类、临床分型和Ct值差异均有统计学意义(P＜0.001),发热是不同变异株感染首发症状中的主要临床特征。不同变异株感染的潜伏期分别为:原始株9.0(5.0,11.0)d,B.1.1.317变异株8.0(4.0,12.0)d,Delta变异株3.5(3.0,9.0)d,Omicron变异株3.0(1.8,5.6)d,差异具有统计学意义(H=42.448,P＜ 0.001)。原始株感染者的中位代间距为6.0 d,Omicron感染者为3.0 d。结论 Omicron变异株传染性强,更易引起隐匿传播。
Abstract
Objective To analyze the epidemiological indicators and clinical manifestations of coronavirus disease 2019 (COVID-19) with different variants,and to provide a reference for the prevention and control of SARS-CoV-2. Methods The data on social demographic characteristics,epidemiological characteristics,clinical manifestations,and laboratory tests of COVID-19 cases in Anhui Province from 2020 to 2022 were collected.SPSS 21.0 was used to analyze the epidemiological and clinical characteristics of patients infected with different variants. Results A total of 2 416 cases of COVID-19 were included,including 990 cases of original strain infection,22 cases of B.1.1.317 evolutionary branch infection,12 cases of Delta infection,and 1 392 cases of Omicron infection.The differences in case classification,clinical type,and Ct value among different variants of SARS-CoV-2 were statistically significant (P < 0.001),and fever was the main clinical feature of the first symptoms of infection among different variants.Moreover,the incubation periods of different strains were 9.0(5.0,11.0) days for the original strain,8.0(4.0,12.0) days for B.1.1.317,3.5(3.0,9.0) days for Delta,and 3.0(1.8,5.6) days for Omicron,and the differences were statistically significant (H=42.448,P＜ 0.001).The median generational interval was 6.0 days in the original strain and 3.0 days in the Omicron variant. Conclusion The Omicron variant of SARS-CoV-2 is more infectious than other strains,and is more likely to result in hidden transmission.
关键词
新型冠状病毒 /
变异株 /
潜伏期 /
代间距 /
续发率 /
临床症状
Key words
SARS-CoV-2 /
Variant /
Incubation period /
Generation gap /
Secondary attack rate /
Epidemiological characteristics /
Clinical symptoms
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] World Health Organization.WHO Coronavirus (COVID-19) Dashboard[EB/OL].(2023-09-22)[2023-09-22].https://covid19.who.int/.
[2] World Health Organization.Weekly epidemiological update 25 February 2021[EB/OL].(2021-02-25)[2023-03-21].https//www.who.int/publications/m/item/covid19weeklyepidemiologicalupdate.
[3] World Health Organization.Tracking SARS-CoV-2 variants[EB/OL].(2021-12-06)[2023-03-21].https://www.who.int/en/activities/trackingSARS-CoV-2-variants/.
[4] World Health Organization.Weekly epidemiological update on COVID-19 - 21 September 2021[EB/OL].(2021-09-21)[2023-09-22].https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---21-september-2021.
[5] Viana R,Moyo S,Amoako DG,et al.Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa[J].Nature,2022,603(7902):679-686.
[6] Grant MC,Geoghegan L,Arbyn M,et al.The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2;COVID-19):a systematic review and meta-analysis of 148 studies from 9 countries[J].PLoS One,2020,15(6):e0234765.
[7] Menni C,Valdes AM,Polidori L,et al.Symptom prevalence,duration,and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance:a prospective observational study from the ZOE COVID Study[J].Lancet,2022,399(10335):1618-1624.
[8] Graham MS,Sudre CH,May A,et al.Changes in symptomatology,reinfection,and transmissibility associated with the SARS-CoV-2 variant B.1.1.7:an ecological study[J].Lancet Public Health,2021,6(5):e335-e345.
[9] Lai CC,Shih TP,Ko WC,et al.Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19):the epidemic and the challenges[J].Int J Antimicrob Agents,2020,55(3):105924.
[10] Rothe C,Schunk M,Sothmann P,et al.Transmission of 2019-nCoV infection from an asymptomatic contact in Germany[J].N Engl J Med,2020,382(10):970-971.
[11] 周燕.广州市一起新型冠状病毒Delta变异株暴发疫情的传播特征和防控效果评估研究[D].广州:南方医科大学,2022.
[12] 潘静静,王莹莹,王文华,等.一起由奥密克戎变异株 BA.2.2 引起的河南省新冠肺炎本土疫情流行病学特征分析[J].中国公共卫生,2022,38(8):975-979.
[13] 邱玉冰,贾曼红,陈金瓯,等.云南省边境地区由新冠病毒原型株和奥密克戎变异株引起的两起新冠肺炎疫情流行特征对比分析[J].中国公共卫生,2022,38(9):1175-1180.
[14] 马钰,马蒙蒙,罗业飞,等.广州市新型冠状病毒肺炎密切接触者感染危险因素分析[J].中国公共卫生,2020,36(4):507-511.
[15] World Health Organization.Enhancing readiness for omicron (B.1.1.529):technical brief and priority actions for member states[EB/OL].(2021-01-21)[2023-03-21].https://www.who.int/publications/m/item/enhancing-readiness-foromicron-(b.1.1.529)-technical-brief-and-priority-actions-for-member-states.
[16] Majumder J,Minko T.Recent developments on therapeutic and diagnostic approaches for COVID-19[J].AAPS J,2021,23(1):14.
[17] 郭倩,黄明月,龚磊,等.新型冠状病毒肺炎最新研究进展[J].安徽预防医学杂志,2022,28(3):234-238+254.
[18] 李亚飞,范威,王文华,等.一起由新冠病毒奥密克戎变异株引起的学校聚集性疫情[J].中国公共卫生,2022,38(5):614-618.
[19] 乔旭界,陈素凤,邱永强,等.新冠肺炎疫情期间农村地区的防疫措施及启示[J].江苏卫生事业管理,2021,32(5):685-688+692.
[20] 中华人民共和国中央人民政府.“乙类乙管”正式实施,国务院联防联控机制要求确保疫情防控转段平稳有序[EB/OL].(2023-01-09)[2023-03-21].http://www.gov.cn/xinwen/2023-01/09/content_5735926.htm.
基金
2022年安徽省新冠病毒科研应急攻关项目(2022e07020071)
PDF(763 KB)
